Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.
Juno Corporate Presentation - January 2018
|Summary Toggle Jan 9, 2018 at 4:30 PM PST|
|Summary Toggle Jan 9, 2018 at 4:00 PM PST|
|Summary Toggle Dec 11, 2017 at 8:30 PM EST|
Copyright Nasdaq. Minimum 15 minutes delayed.